Redeye provides a research update following the Q4 report published by ExpreS2ion earlier today. Overall, the report did not contain any financial surprises. The company continues its low operating expense and cash burn level, even as the dose-escalation part of its phase I trial with ES2B-C001 is now in full swing. With encouraging initial data and progress in the company’s partner-led programs, we argue that ExpreS2ion is on a promising trajectory.
LÄS MER
